1 CONFIDENTIAL INFORMATION CONFIDENTIAL INFORMATION
2 CONFIDENTIAL INFORMATION 2 CONFIDENTIAL INFORMATION 2 CONFIDENTIAL INFORMATION
Aerolase Develops, Manufactures and Markets
the Next Gen Lasers for Aesthetics and Dermatology
Fast Growth Global Market, Fueled by: - Aging population mix
- Globally rising middle class
- Universal need to be young/attractive -- ”Look good, feel good”
Medical
Dermatology
Aesthetics/
Anti-Aging
3 CONFIDENTIAL INFORMATION 3 CONFIDENTIAL INFORMATION 3 CONFIDENTIAL INFORMATION
Unique Portability
Typical Competitor
Top Efficacy
1 Aerolase Laser Replaces
4 Rival Lasers
Unique Versatility:
Best Safety
Aerolase Has Reinvented Dermatology Lasers
4 CONFIDENTIAL INFORMATION
5 CONFIDENTIAL INFORMATION
6 CONFIDENTIAL INFORMATION 6 CONFIDENTIAL INFORMATION 6 CONFIDENTIAL INFORMATION
Portability Top Efficacy/Safety
All In One Device -- LightPod® Laser from Aerolase
Unique Versatility
Aerolase Is The iPhone of Dermatology Lasers
7 CONFIDENTIAL INFORMATION 7 CONFIDENTIAL INFORMATION 7 CONFIDENTIAL INFORMATION
Broad Takeaways on Aerolase Opportunity
• Next Generation Dermatology Laser Technology = The iPhone of Dermatology Lasers
• Rapidly gaining major share from all including largest rivals; 76% laser rev growth rate
2019
• 80%+ gross margin; EBITDA profitable.
• Replicating U.S. success worldwide
• Rich IP developed in-house, prized by world-class collaboration partners such as global
skincare giant Beiersdorf (Deutsche Börse: BEI) and cardio device innovator
Cardiovascular Systems, Inc (NASDAQ:CSII); also advanced topical companies such as
SENTÉ and PCA Skin
• Compelling comparable company datapoints
• Clear avenues to exit
8 CONFIDENTIAL INFORMATION 8 CONFIDENTIAL INFORMATION
Aesthetic Device Market Growing Rapidly, Sustainably and Globally
• Botox, fillers, topicals lead base market but cannot deliver full
results without lasers
• Aesthetic lasers in high demand everywhere aided by managed
care devastating U.S. doctors’ incomes (aesthetic Tx are patient
self-pay)
• All such lasers except Aerolase are bulky and cumbersome, costly
to acquire and operate, and for patients produce pain/discomfort
and downtime
0
2
4
6
2020 2025
Global Aesthetic Device Market (in $B)
researchandmarkets.com
9 CONFIDENTIAL INFORMATION 9 CONFIDENTIAL INFORMATION 9 CONFIDENTIAL INFORMATION
Aerolase Serves Immense Medical Dermatology Markets
And Does So Better than Drug/Medication Solutions
0
5
10
15
20
25
30
2020 2025
Global Medical Dermatology Market (in $B)
Acne
Onychomycosis
Psoriasis
Sources: https://www.statista.com/statistics/717599/global-acne-treatment-market-size/ Onychomycosis Market Research Report - Global Forecast till 2025. ID:MRFR/Pharma/0832-CR | September, 2019 https://www.marketresearchfuture.com/reports/onychomycosis-market-1340 https://www.marketresearchfuture.com/reports/psoriasis-treatment-market-2769
• Acne, Psoriasis, Nail Fungus are widespread medical conditions that
have severe psychological impact on sufferers, frequent cause of
depression and suicide
• Drugs have serious risks/side effects: birth defects in pregnant women,
liver disorders, elevate risk of life-threatening infections such as HIV and
tuberculosis; many others
• Aerolase laser has no side effects and delivers efficacy similar to drugs
• Aerolase is gaining share of these huge markets
10 CONFIDENTIAL INFORMATION 10 CONFIDENTIAL INFORMATION 10 CONFIDENTIAL INFORMATION
Aerolase Laser Is A Compelling Buy for Each Segment
14K Dermatologists
7K Plastic Surgeons
275K Primary Care Doctors (mostly “GP’s”)
5.5K Medspas
Western Europe
Similar to U.S. (though managed care pressures on GP’s less
severe)
Market Profiles:
U.S.
Emerging Markets
Booming, bigger than U.S., fewer Medspas
Aerolase Winning in All Segments of Laser Dermatology Worldwide
Aerolase Growing Strongly in All Segments
39%
30%
25%
6%
2019 Revenues by Specialty
Spa Derm GP Plastic
$-
$1,000,000
$2,000,000
$3,000,000
$4,000,000
$5,000,000
$6,000,000
Plastic Derm Spa GP
2017
2018
2019
11 CONFIDENTIAL INFORMATION 11 CONFIDENTIAL INFORMATION 11 CONFIDENTIAL INFORMATION
Aerolase Gaining Market Share, Growing 6x vs. Competition
Percentage Revenue Change
Aerolase vs. Direct Competitors
Full Year 2019 Q4 2019 Guidance 2020
US TOTAL US TOTAL US TOTAL
Alma 7 9 NA NA NA NA
Cutera 4 12 11 14 1 9
Cynosure -9 -7 NA NA 0 3
InMode 52 56 61 63 26 24
Solta 5 44 4 42 3 38
Average 12 23 25 40 8 19
Aerolase 70 76 60 67 50 52
Sources : Publ ic company disclosed data; Alma and Cynosure closely approximated
due to reporting gaps
12 CONFIDENTIAL INFORMATION 12 CONFIDENTIAL INFORMATION
Example: InMode IPO Aug 2019 (NASDAQ: INMD)
• Up 3x IPO price, $1.5B enterprise value, trading at 8x est 2020 revs and 17x EBITDA (at 2/20/20)
• Aerolase treats same aesthetic treatments but in addition delivers strong efficacy in key medical dermatology disease states
InMode (NASDAQ:INMD) vs. Aerolase Treatment Comparison
Treatments Provided/Promoted InMode Aerolase Aerolase Efficacy
Acne Scars Yes Yes Parity
Facial Rejuvenation Yes Yes Better
Hair Removal Yes Yes Better
Skin Tightening, face, neck Yes Yes Parity
Vascular/Pigmented Lesions/Rosacea Yes Yes Better
Skin Tightening, body/fat reduction Yes Coming 2020-2021 Targeted better
Vaginal Rejuvenation Yes Coming 2020-2021 Targeted better
Darker skintones, heat-based treatments Yes Yes Parity or better
Darker skintones, light-based treatments No Yes Best in device industry
Active Acne No Yes Best in device industry
Melasma No Yes Best in device industry
Nail Fungus No Yes Parity with best
Psoriasis No Yes Parity with best
Woundhealing/decubitis ulcers No Yes Parity with best
Ablative Resurfacing No Yes Parity with best
Note: Aerolase also better than InMode on key patient attributes like discomfort and downtime
Strong Investor Interest in Sector
13 CONFIDENTIAL INFORMATION 13 CONFIDENTIAL INFORMATION 13 CONFIDENTIAL INFORMATION
Analysis of Strategic Buyer Acquisitions in Aesthetic Sector
Total
Multiple Consideration
Deal Acquirer/ on: net of cash, debt
Date Target Enterprise Value/EBITDA Sales $M Remarks
2/2020 Eli Lilly/Dermira NM--negative EBITDA 30.1 1100
5/2019 EQT Consortium/Galderma -- 3.6 10,100 Galderma underperforming due to years of ownership uncertainty
1/2019 ConMed/Buffalo Surgical Filter 25.5 7.5 365 Includes synergies claimed but unclear; multiples higher ex-synergies
2/2017 Hologic/Cynosure 23.0 3.3 1457 Multiple bids, only 15% of revenues from innovative spaces
2/2017 Allergan/Zeltiq 59.3 6.8 2,412 Zeltiq growth rate probably peaked, competiton flooding into its space
5/2016 Pfizer/Anacor NM--negative EBITDA 24.9 5,200 Based on projected 2017 revenues if lead product approved
11/2015 Pfizer/Allergan 9.2 9.0 160,000 Withdrawn April 2016 due to government action
6/2015 Allergan/Kythera 30.8 9.0 2,100 Paid on 2017 projected metrics
11/2014 Actavis/Allergan then renamed Allergan 20.5 9.2 66,000
6/2014 Merz/Ulthera 27.0 6.7 600 Ulthera first ultrasound device for skin tightening certain facial areas
2/2014 Nestle/Galderma 22.0 3.9 4,247 for the 50% stake owned by L'Oreal
4/2013 Valeant/Obagi 19.7 3.5 420 Obagi considered badly managed
12/2012 Valeant/Medicis 16.2 13.2 2,570
6/2008 Medicis/Liposonix NM--negative EBITDA 150.0 300 $150M upfront +$150M milestones mostly for FDA approval which did occur
Median 22.5 8.3
Mean 25.3 20.1
Average of above 23.9 14.2
Intense M&A Activity in Aesthetics, Few Attractive Companies Left
14 CONFIDENTIAL INFORMATION 14 CONFIDENTIAL INFORMATION
Aerolase is an Emerging Leader with Booming Market Recognition
• We are a vertically integrated company with all functions successfully built in house –
Aerolase invents, develops, manufactures, markets and sells
• 2019 vs. 2018 laser revenue growth = 76%
• Strong global IP protection 20 patents in US, 5 in 23 countries
• 1300+ lasers sold since inception in 45 countries (75% in US), dominant market share
in some regions
• 31 world-renowned Key Opinion Leader users; consumer brand equity from powerful
celebrity endorsements (e.g. Kathie Lee, Elle Macpherson) and prime media (e.g.
Today Show)
• Aerolase is attracting attention from dermatology pharma companies. Galderma
selected Aerolase for its global Innovation Centers (SHIELD).
• Best Laser 2020, 2019, and #1 Hair Removal Laser 2018 and 2017, as ranked from
30K user base of Dermascope/Aesthetic International Association
15 CONFIDENTIAL INFORMATION 15 CONFIDENTIAL INFORMATION 15 CONFIDENTIAL INFORMATION
Coming Soon:
Aerolase’s benefits prized/taught by top med schools, dermatology academies worldwide
Hamburg, Germany
16 CONFIDENTIAL INFORMATION 16 CONFIDENTIAL INFORMATION 16 CONFIDENTIAL INFORMATION
• Launched 2015, now 20K followers on Instagram, far more than larger revenue rivals such as Cynosure,
Candela, Lumenis, Cutera
• Aerolase follower community engaged: average per post = 500 likes, 25 comments, 10 direct messages;
average 6K views per video
• High visibility Aerolase practitioners/Instagram stars include:
Jason Emer, Beverly Hills: 175K follower
Aivee Teo, Philippines: 139K
Michelle Henry, NYC: 61K
Holly Cutler, Michigan: 50K
Nabil Fakih, Lebanon: 17K
Social Media Marketing a Distinctive Competence
Celebrity Patients Praising Aerolase Treatments:
Elle Macpherson
Kathie Lee
17 CONFIDENTIAL INFORMATION 17 CONFIDENTIAL INFORMATION 17 CONFIDENTIAL INFORMATION
Superiority on the key laser attributes >> compelling unmatched practitioner ROI
Aerolase Has Sweeping Advantages over All Competition
Gaining Share and Growing Much Faster than the Market
1. Efficacy
2. Versatility
3. Safety
4. Performance on darker skin tones (Mid Eastern, Asian, Indian, Black)
5. Reliability/minimal servicing
6. No patient pain
7. No/minimal patient downtime
8. Low cost of goods >>> affordable price to obtain
9. Low operating cost >>> no hidden costs to user
10. Only portable high power dermatology laser in world
18 CONFIDENTIAL INFORMATION 18 CONFIDENTIAL INFORMATION
Key Differentiator #1:
Minimizes mechanical parts, needed only for water cooling, so through are gone
including their cost and need for repair, resulting in higher margins for Aerolase.
The only portable high power multi-application dermatology laser, enabled by
strongly patented air-cooled design:
1 6
Typical
Competitor
Aerolase
19 CONFIDENTIAL INFORMATION 19 CONFIDENTIAL INFORMATION 19 CONFIDENTIAL INFORMATION
Portability Brings Many Big Advantages for User
• Saves treatment room space – key in big cities
• Allows sharing device between locations--more
practice revenue out of same asset
• Highly reliable vs. frequent downtime (because
eliminates trouble-prone subsystems)
• Ease of service worldwide (units easily shipped for
repair by overnight carrier)
• Consistent w growing trend of at-home aesthetic
services by mobile practitioners, which could well
take off due to Coronavirus
-- U.S., Europe, Middle East leading the trend
20 CONFIDENTIAL INFORMATION 20 CONFIDENTIAL INFORMATION 20 CONFIDENTIAL INFORMATION
Key Differentiator #2:
Single Aerolase Neo® laser has EFFICACY AS GOOD OR BETTER in delivering
range of treatments that requires 4 separate devices from a typical competitor
Unique Versatility via Optimal Parameters, Novel 650-Microsecond Technology
1>4!
• Aerolase laser cost to practitioner – $115-130K; vs. $400K+ for 4 competitor lasers
• This is a winning proposition for every market from U.S./Western Europe to least developed regions
Melasma
& Hyperpigmentation Hair Removal
& Veins Acne &
Skin Rejuvenation Psoriasis
Aerolase Neo
21 CONFIDENTIAL INFORMATION 21 CONFIDENTIAL INFORMATION 21 CONFIDENTIAL INFORMATION
Key Differentiator #3:
Aerolase unique efficacy on acne desired in most advanced aesthetic practices
- 650 million individuals have acne globally, $7.35B market by 2025
- Acne drugs have severe side effects
Before and After 5 Aerolase Treatments
Clinical Assistant Professor at
Vanderbilt University School of
Medicine, Adjunct Assistant
Professor at Meharry Medical
College School of Medicine,
Visiting Professor of Dermatology
or Plastic Surgery at various
institutions in China.
Play from Movie Link #1 in
Email Or click - https://youtu.be/5-tWBYJhsKs
ACNE
Testimonial and Footage Courtesy of
Michael Gold, MD, Dermatologist
22 CONFIDENTIAL INFORMATION 22 CONFIDENTIAL INFORMATION
Key Differentiator #4:
Aerolase unique efficacy on psoriasis was recently affirmed by randomized,
investigator-blinded, parallel-group study with 20 subjects with mild to moderate psoriasis
vulgaris
PSORIASIS
Before and After 4 Aerolase Treatments
8 million patients in the U.S.
2.5% of world population afflicted
Global market $13.1B by 2025
Laser psoriasis treatment is
reimbursable in the U.S. at ~$160-
170 per small lesion and ~$260-270
for a large area
Psoriasis drugs have severe side
effects
23 CONFIDENTIAL INFORMATION 23 CONFIDENTIAL INFORMATION
Key Differentiator #5:
Aerolase increasingly acknowledged as the best laser/device option for melasma
Before and After 2 Treatments Leading dermatologist in
New Jersey and KOL for
acne, melasma, and
psoriasis.
Play from Movie Link
#3 in Email
Or click https://youtu.be/xCd6qngXSVk
Testimonial and Footage Courtesy of:
Karen Harkaway, MD, Dermatologist
Photos courtesy of Avanti Aesthetics Clinic – Harley St. London UK
Before and After 1 Treatment
Melasma: widespread pigmentation disorder hated by sufferers, has no clear solution
today. $8.5B Global Market by 2024.
24 CONFIDENTIAL INFORMATION 24 CONFIDENTIAL INFORMATION 24 CONFIDENTIAL INFORMATION
Key Differentiator #6:
Unique efficacy on most aesthetic treatments with less patient discomfort and
downtime than any competitor
Before and After 1 Aerolase Treatment
Beverly Hills-based
“Dermatologist to the stars”
Trained with top
dermatology laser experts
at Mount Sinai and Bay
Area Laser Institute. A
leading expert in facial and
body rejuvenation with
lasers.
Play from Movie Link
#2 in Email
Or click - - https://youtu.be/qWhcUQQ9kOg
FACIAL REJUVENATION Testimonial and Footage Courtesy of
Jason Emer, MD, Dermatologist
Photos courtesy of James Newman, Premier Plastic Surgery – San Francisco
25 CONFIDENTIAL INFORMATION 25 CONFIDENTIAL INFORMATION 25 CONFIDENTIAL INFORMATION
Key Differentiator #7:
Aerolase Delights Patients + Docs with Unmatched Treatment Comfort
Play from Movie Link #3 in Email or click https://youtu.be/EXqXSLfalqU
Footage courtesy of NBC Universal Today Show with
Kathie Lee Gifford, November 1, 2018
Patients
• No treatment pain without numbing (anesthetic)
• Highly hygienic -- device tip does not touch the skin
• Cooling gels application to skin is eliminated. No
more mess and expense for practitioner and patient
Practitioners
• Comfort Favorable Word of Mouth
• Lack of pain optimizes office throughput
• Patient not jumping off table mid-procedure
• Minimal patient prep due to no numbing
• Procedure time predictable and faster
26 CONFIDENTIAL INFORMATION 26 CONFIDENTIAL INFORMATION
Key Differentiator #8:
Aerolase is Uniquely Safe and Comfortable on Dark Skin Tones and Tanned Light Skin
Play from
Movie Link
#4 in Email
Or click - https://youtu.be/sdIuwGnT-XY
Testimonial and Footage Courtesy of:
Wendy Roberts, MD, Dermatologist
• It is a major challenge for conventional
technology to treat dark skin -- Black,
Middle Eastern, Indian, Asian, even
tanned white skin
• Aerolase 650-microsecond technology is
a game changer for many U.S.
dermatologists who avoid treating skin of
color because of high risks
• Key advantage for largely untapped vast
emerging markets of China, India, Brazil,
Africa, other
Leading dermatologist for skin of color and founder of Roberts Skin Type Classification
Scale
27 CONFIDENTIAL INFORMATION 27 CONFIDENTIAL INFORMATION
Key Differentiator #9: Aerolase Delivers Unmatched ROI to Practitioner
• Superiority on the key laser attributes >> compelling unmatched practitioner ROI
• Typical payback period on laser cost within 5 months, can generates revenue up to $1M/yr or more
-
Revenue Estimator for Aerolase LightPod Neo Elite Laser
Application
# of New
Clients per
month
Tx Time
(minutes)
Avg. Fee per
Treatment
($)
Avg. #
of Tx
Total Annual
Revenues ($)
Acne Clearance 4 15 350$ 4 67,200$
Spider Veins 8 5 300$ 2 57,600$
Rosacea 4 15 350$ 4 67,200$
Psoriasis (CPT codes 96920-22) 8 20 175$ 12 201,600$
Sun Spots, Pigmented Lesions 1 15-20 350$ 3 12,600$
Melasma 2 25-30 500$ 4 48,000$
Face/Neck Skin Tightening/Rejuvenation 4 25-30 450$ 4 86,400$
Decolletage Skin Rejuvenation 2 20-25 450$ 4 43,200$
Hands Photorejuv 2 20-25 250$ 4 24,000$
Hair Removal (upper lip) 4 10-15 100$ 6 28,800$
Hair Removal (facial area) 2 10-15 150$ 6 21,600$
Hair Removal (armpits) 4 10-15 250$ 6 72,000$
Scars 2 15-20 250$ 4 24,000$
Nail Fungus 2 15 250$ 4 24,000$
Warts/skin tags/angiomas 8 5 200$ 4 76,800$
$855,000
Psoriasis 96920-96922: Laser Treatment for Inflammatory Skin Disease (Psoriasis); --
$165-$252
Destruction of Lesions 17000-17004: Pigmented Lesions, Skin Tags, Other Lesions
Destruction, Benign Lesion, any method -- $75-$175
Port Wine Stains & Large Strawberry Hemangiomas 17106-17108: Destruction of
cutaneous vascular proliferative lesions (e.g. laser technique); -- $375-$875
Warts 17110-17111: Warts Destruction by any method of flat wart, molluscum or milia -
- $100
Debridement 97597: Wound Healing (Laser Debridement) Selective Debridement
without Anesthesia -- $50
CPT Codes and Reimbursement Rates For Aerolase Medical Treatments
28 CONFIDENTIAL INFORMATION
28
Expert User Testimony: Aerolase Neo® – Highest ROI
“The most constantly used, and biggest profit center laser in my practice of 45 lasers”
– Michael Gold, Dermatologist Gold Skin Care Center Nashville, TN
“I generated $1.5M in a year with one Neo laser” – Medi Neyastanki, CEO & Founder Spade Skin Care & More Los Angeles Metro
“ Neo delights my very most demanding and laser-savvy patients, and is so versatile that I generated new revenues in excess of the laser cost in just a few months. I’m vigilant on ROI and Neo stand outs on that.”
-- Roberta Del Campo, Dermatologist – Del Campo Dermatology & Laser Institute Miami
It’s versatile, with hardly any maintenance. It’s portable, it’s safe, it’s effective. It’s a no brainer.
-- Arusha Campbell-Chambers, Dermatologist Montego Bay, Jamaica
“Neo is our workhorse . We just purchased our third one. The office has many other devices, all of which are sitting untouched in the laser graveyard typical of many practices .”
-- Jason Staback, PA-C Dermatology Northern NJ
29 CONFIDENTIAL INFORMATION 29 CONFIDENTIAL INFORMATION
Many Innovative Pipeline Products on the Way
Each Has Different Parameters Optimized for the Target Treatments and User Segments
Three Main Lasers in Present Line-Up
30 CONFIDENTIAL INFORMATION 30 CONFIDENTIAL INFORMATION 30 CONFIDENTIAL INFORMATION
Historic and Near Term Financial Profile, pre-growth capital raise
• +76% Laser Revenues 2019 vs. 2018
• Robust growth across all parts of the business
• Positive EBITDA despite substantial discretionary
long term growth investments in SG&A
Fiscal years ending Dec, $K:
2016A 2017A 2018A 2019A 2020
Revenues 4,205 6,556 7,528 13,063 18,000
EBITDA 335 1,378 1118 3,052 3,675
2019 Financial Highlights:
Notes: Gross Margin > 80%. 2018 and 2019 exclude non-recurring items and planned elevation of discretionary SG&A investment ahead of revenues to drive volume to critical mass levels.
$-
$1,000,000
$2,000,000
$3,000,000
$4,000,000
$5,000,000
$6,000,000
Q1 Q2 Q3 Q4
Quarterly Revenue
2017
2018
2019
31 CONFIDENTIAL INFORMATION 31 CONFIDENTIAL INFORMATION 31 CONFIDENTIAL INFORMATION
Financial Plan Post-Growth Capital Raise
2019A 2020 2021 2022 2023
Revenues 13,063 21,970 43,030 64,855 85,177
EBITDA 3,052 4,000 9,375 16,500 24,775
Conservative Base Plan Reflects sales of Aerolase products already in the market, assumes $10M raise Q1 2020:
Revenue upside ($K) from new product intro’s being accelerated, assuming additional $15M growth raise Q1 2020:
2019 2020 2021 2022 2023
0 1,294 13,868 42,163 109,186
($K)
($K)
32 CONFIDENTIAL INFORMATION 32 CONFIDENTIAL INFORMATION 32 CONFIDENTIAL INFORMATION
Aerolase Already Tripled Salesforce Within Last 12 months
VP US Sales = 1
Main Use of Investment to Expand U.S. Salesforce to Cover All Key Markets
Current and Near Term Targeted Coverage
Current U.S. = 23
Corp. HQ Tarrytown, NY
EMEA
Return on Salesforce Investment (ROSI)
Average Salesperson/Month:
$10K fixed all-in (incl t&e)
+ $6K commission
= $16K Total Cost
Revenue generated/mo $62.5K, <1 laser
Gross Margin 85% $53.1K
ROSI= 3.3x, (53.1÷16)
New hire typically sells 1st laser within 4 months -
already +$37K ROSI
To be added over next
12 months, resulting in
40 salesperson territories
covering major market areas
In training 6 of
fewer mos. tenure = 7
Semi-trained
6–12 mos. tenure = 3
Fully trained
12+ mos. tenure = 10
Regional Sales Manager = 2
33 CONFIDENTIAL INFORMATION 33 CONFIDENTIAL INFORMATION 33 CONFIDENTIAL INFORMATION
Main Use of Proceeds
Accelerating Financial Performance, Strategic Expansion via High Return/Low Risk Projects
Aerolase is growing rapidly through internal EBITDA but would apply
growth equity proceeds as follows:
• Accelerate U.S. direct sales expansion to cover all U.S. territories replicating successful sales model
o Buildout in line with major competitors should generate an incremental $100M revenues over 5 years
o Plan results highly visible -- Aerolase wins order on most demos (high close rate) including against biggest competitors
• Step up U.S. and global marketing
• Accelerate International channels buildout -- Int’l could well be > 50% of revs.
• Fund further KOL network and support globally to broaden awareness of Aerolase superiorities
• Accelerate commercialization of pipeline products which would also generate large recurring revenue streams
34 CONFIDENTIAL INFORMATION 34 CONFIDENTIAL INFORMATION 34 CONFIDENTIAL INFORMATION
Post New Investment Aerolase Revenue Ramp Plan Follows Classic Trajectory
Actual Revenues Demonstrated by Prior Aesthetic Device Innovators
During Their First 3 Years Post Full Commercialization Funding ($25M average investment) Graph indication is conservative as Aerolase has a bigger addressable market
1 2
3
120
100
80
60
40
20
0
Fraxel
Syneron
Ulthera
Zeltiq
Thermage
Reported
Revs $M
Years Post-Full Financing
35 CONFIDENTIAL INFORMATION 35
Management Skilled in Executing Growth Ramp and Adding Shareholder Value, part 1
Pavel Efremkin, PhD—Founder, CEO, CTO
Successful serial entrepreneur, built Aerolase from vision of unmet market need to a profitable global emerging leader. Built and led all functions in vertically integrated
medical device company including, at various times, IP creation, R&D, regulatory, clinical research, manufacturing, sales, and marketing.
Raised early seed growth capital from institutional and family office sources, and others
Entered into strategic collaborative development agreement with $2B market cap Cardiovascular Systems Inc. (NASDAQ: CSII), entailing multimillion dollar equity
investment in Aerolase
Author of 20+ U.S. patents + many international
Graduate degrees magna cum laude in physics, technology—Moscow State University (a premier science university of world class caliber); PE/VC Executive Program--
Harvard Business School
Joe Hurley—COO
Top executive at OK Industries, pivotal role in OK being acquired by Advent (PE firm) then sold to public conglomerate Dover Industries
Co-built Aerolase starting 2004, built and led sales, marketing quality management, and HR functions
Dual BS Mechanical Engineering & Materials Science-UConn, MBA magna cum laude-Northeastern Univ.
Kathy Walton—VP of U.S. Sales
9 years of sales management at Aerolase, Nestlé/Galderma and Eclipse medical, 16 years in dermatology sales
Leveraged relationships with Key Opinion Leaders in dermatology to accelerate sales and elevate brand profile
Rapidly scaled Aerolase U.S. sales team and productivity to achieve > 80% revenue growth year over year, turned around underperforming regions
Gary M. Giblen– Director of Corporate Development
Previously #1-ranked Wall Street analyst in sector/Director of Research; Recognized for finding/assisting major emerging growth winners
Leads strategic, partnering, investor and capital raising activities at Aerolase; created Aerolase Business Advisory Board of industry luminaries in finance, strategy
Instrumental in strategic collaborative development agreement with $2B market cap Cardiovascular Systems Inc. (NASDAQ: CSII), entailing multimillion dollar equity
investment in Aerolase
BA Yale, MBA Harvard
36 CONFIDENTIAL INFORMATION 36
Management Skilled in Executing Growth Ramp and Adding Shareholder Value, part 2
Nicolas Maurer --Director of Business Development/Marketing Europe, Middle East, Africa
Former CCO Establishment Labs (ESTA:NASDAQ -- breast implant co) as it flourished to $300M enterprise value IPO under PE sponsorship (now $550M )
Proven leader in global dermatology brand marketing and sales., VP Marketing Beiersdorf in German and US HQ, responsible for global skincare brands Nivea,
Eucerin, Aquaphor; 18 years in aesthetic marketing.
Successfully expanded Aerolase KOL and partner network in Europe.
John Lenihan--Director of Sales Europe, Middle East, Africa
Seasoned and successful sales leader built and managed EMEA sales organizations for Cutera and Cynosure; CCO Energist – a leading UK based aesthetic laser company. 24 years in dermatology laser sales.
Successfully launched 11 distributors for Aerolase since 2018.
Sean Johnson—Director of U.S. Marketing
7 years progressive responsibilities in all facets of dermatology laser marketing strategy and execution.
Led Aerolase marketing team from start up to acknowledged excellence particularly in social media.
37 CONFIDENTIAL INFORMATION 37 CONFIDENTIAL INFORMATION 37 CONFIDENTIAL INFORMATION
Aerolase Technology Advantages Can Be Swiftly Commercialized Into
Big Medical Verticals Outside Present Core
• Unique in-house R&D know-hows translate very well to other
verticals:
• Investment in the new verticals portfolio could be in a
separate entity or as part of core Aerolase Corp.
o Vast expertise in design and manufacturing of uniquely
portable high power medical lasers
o Deep clinical understanding of lasers’ effects on live tissue
o Proven leadership in inventing laser treatments delivering
new levels of efficacy and safety
38 CONFIDENTIAL INFORMATION
DISCLAIMER
This presentation is designed to help potential investors better understand the potential risks, costs and benefits of this company, but
it is not intended, and is not to be considered, as an investment offer or solicitation, which may be regulated by law. This presentation
does not purport to be all-inclusive nor to contain all information that a prospective investor may desire in investigating this company.
Each prospective investor must rely on his or her own examination of the potential investment and the terms of the proposed
investment, including the merits and risks involved in making an investment decision.
The contents of this presentation should not be construed by prospective investors as investment, tax or legal advice. Investors are
advised to exercise caution when considering investment alternatives because actual data may differ from projections. Prior to
making an investment decision regarding the proposed investment, a prospective investor is urged to consult his or her own counsel,
accountants and other advisors.
The information contained in this presentation is confidential and proprietary and is being submitted to prospective investors solely for
such investors' confidential use with the express understanding that such persons will not release this document or discuss the
information contained herein or make reproductions of or use this presentation for any purpose other than evaluating a potential
investment in the company.
36 CONFIDENTIAL INFORMATION